Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tetsuya Isaka
Impact of the Epidermal Growth Factor Receptor Mutation Status on the Prognosis of Recurrent Adenocarcinoma of the Lung After Curative Surgery
BMC Cancer
Cancer Research
Oncology
Genetics
Related publications
Impact of Epidermal Growth Factor Receptor Mutation Status on Outcomes for Lung Adenocarcinoma Brain Metastases Following Radiosurgery
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Significance of the Epidermal Growth Factor Receptor Mutation Status and Differences Among Molecular Subgroups in Surgically Resected Lung Microinvasive Adenocarcinoma
Oncology Letters
Cancer Research
Oncology
SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma
Oncologist
Cancer Research
Medicine
Oncology
Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma
Annals of Thoracic Surgery
Respiratory Medicine
Pulmonary
Cardiovascular Medicine
Surgery
Cardiology
Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report From Iran
Impact of Epidermal Growth Factor Receptor Gene Expression Level on Clinical Outcomes in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Patients Taking First-Line Epidermal Growth Factor Receptor–tyrosine Kinase Inhibitors
Tumor Biology
Medicine
Cancer Research
Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Recurrent Adenosquamous Carcinoma of the Lung After Resection
OncoTargets and Therapy
Oncology
Pharmacology
The Association of Acquired T790M Mutation With Clinical Characteristics After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Cancer Research and Treatment
Cancer Research
Oncology
